The study found that low expressions of ARNTL or PER2 were significantly associated with metastasis at the moment of disease diagnosis and suggested ARNTL and CRY1 as biomarkers of CRC patient survival and metastasis. The gene discussed is BMAL1; the disease is colorectal carcinoma.